BRCA1 and breast cancer: After the introduction of PARP (polyadenosine diphosphate ribose polymerase) inhibitors as a therapy of choice for BRCA1/2-related HBOC, the differentiation between genetic and sporadic breast cancer became increasingly important [57, 58].